Respirology Search
Respirology Respirology
bronchitis%20-%20uncomplicated%20acute
BRONCHITIS - UNCOMPLICATED ACUTE
Uncomplicated acute bronchitis is a self-limiting infection of the trachea and bronchi that usually lasts for 1 to 3 weeks. A healthy patient experiences sudden onset of cough, with or without sputum production.
It is an inflammatory response to infections of the bronchial epithelium of the large airways of the lungs that begins with mucosal injury, epithelial cell damage and release of proinflammatory mediators.
There is transient airflow obstruction and bronchial hyperresponsiveness.
Purulence can result from either bacterial or viral infection.

Bronchitis - Uncomplicated Acute Drug Information

Drug Information

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Indication: Upper & lower resp tract infections, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicat...

Indication: Upper & lower resp tract, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicated gonococc...

Indication: Acute & chronic bronchopulmonary diseases associated w/ abnormal mucus secretion & impaired mucus tran...

Indication: Acute & chronic diseases of the resp tract especially chronic bronchitis, asthmatoid bronchitis, bronchial...

Indication: Reduction of sputum viscosity.

Indication: Otitis media, upper & lower resp tract infections, UTI including pyelonephritis, cystitis, gonococcal uret...

Indication: Upper & lower resp tract, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicated gonococc...

1  /  16
1  /  16
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Mepolizumab: Targeting eosinophils in severe asthma with precision medicine
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
Stopping long-term mepolizumab may lead to exacerbations, loss of asthma control
Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.